Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic DermatitisBusiness Wire • 06/26/26
Here Are Monday's Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More24/7 Wall Street • 06/22/26
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 06/19/26
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Zacks Investment Research • 06/17/26
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA ReviewZacks Investment Research • 06/15/26
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaBusiness Wire • 06/14/26
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential ThrombocythemiaBusiness Wire • 06/13/26
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free SurvivalBusiness Wire • 06/13/26
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands OfferingsInvestors Business Daily • 06/11/26
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2BZacks Investment Research • 06/09/26
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster PotentialBenzinga • 06/09/26
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding DisordersBusiness Wire • 06/08/26
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rateReuters • 05/30/26
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCLBusiness Wire • 05/30/26
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 05/26/26
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll OutMarketBeat • 05/25/26